Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:36:58.345Z.
Calculation as of: 2026-10-06T13:36:58.345Z.
Quote observation: 2026-10-06T13:35:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$70.22M
Price/OCF Ratio
N/A
TTM Avg
1.86
3Y Avg
1.86
5Y Avg
1.86
Market Cap
$70.09M
Price/OCF Ratio
0.56
TTM Avg
0.74
3Y Avg
0.74
5Y Avg
0.74
Market Cap
$68.91M
Price/OCF Ratio
N/A
TTM Avg
15.38
3Y Avg
92.53
5Y Avg
55.53
Market Cap
$77.06M
Price/OCF Ratio
N/A
TTM Avg
338.69
3Y Avg
338.69
5Y Avg
338.69
Market Cap
$79.59M
Price/OCF Ratio
N/A
TTM Avg
786.57
3Y Avg
786.57
5Y Avg
786.57
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $72.51M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $71.38M | N/A | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $70.22M | N/A | 1.86 | 1.86 | 1.86 |
| Fortress Biotech, Inc. (FBIO)vs › | $70.09M | 0.56 | 0.74 | 0.74 | 0.74 |
| Hyperfine, Inc. (HYPR)vs › | $75.89M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $68.91M | N/A | 15.38 | 92.53 | 55.53 |
| MindWalk Holdings Corp. (HYFT)vs › | $77.06M | N/A | 338.69 | 338.69 | 338.69 |
| Gossamer Bio, Inc. (GOSS)vs › | $65.69M | N/A | 35.67 | 35.67 | 35.67 |
| Citius Oncology, Inc. (CTOR)vs › | $79.59M | N/A | 786.57 | 786.57 | 786.57 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $80.15M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
